Skip to content

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Johnson & Johnson logo
Johnson & JohnsonJNJ
-0.2×
Amgen logo
AmgenAMGN
1.3×+0.1×
AbbVie logo
AbbVieABBV
0.8×0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$4.36B+533%
Enterprise value$4.32B+690%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s current ratio?
Oruka Therapeutics, Inc. (ORKA) reported current ratio of 23.8× in Q1 2026.
How has Oruka Therapeutics, Inc.'s current ratio changed year-over-year?
Oruka Therapeutics, Inc.'s current ratio decreased by 20.9% year-over-year, from 30× to 23.8×.
What is the long-term trend for Oruka Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Oruka Therapeutics, Inc.'s current ratio has grown at a 9.4% compound annual growth rate (CAGR), from 14.3× to 22.4×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.